Company Filing History:
Years Active: 1993-1995
Title: Ake Lundwall: Innovator in Recombinant Protein Technologies
Introduction
Ake Lundwall is a notable inventor based in Lund, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant proteins. With a total of 2 patents, his work has implications for therapeutic treatments in various medical conditions.
Latest Patents
Lundwall's latest patents include a recombinant 3-des-OH-cystatin C produced by expression in a procaryotic system. This invention involves the biosynthetic production of a recombinant cystatin C polypeptide, which exhibits higher cysteine proteinase inhibitor activity than native cystatin C. Such preparations are particularly useful in therapeutic treatments for patients suffering from diseases like herpes simplex. Another significant patent involves a vector containing DNA encoding mature human Protein S. This invention discloses a transformed mammalian cell that produces biologically active Protein S, along with the vector used for the transformation, which includes DNA under the control of a eukaryotic metallothionein gene.
Career Highlights
Throughout his career, Ake Lundwall has worked with prominent companies in the biotechnology sector, including Genzyme Corporation and Novo Nordisk A/S. His experience in these organizations has contributed to his expertise in recombinant protein technologies.
Collaborations
Lundwall has collaborated with notable professionals in his field, including Robert Wydro and Edward Cohen. These collaborations have further enhanced his research and development efforts.
Conclusion
Ake Lundwall's innovative work in recombinant protein technologies has paved the way for advancements in therapeutic treatments. His contributions continue to impact the field of biotechnology positively.